Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ziftomenib + olutasidenib
- Development stage
- Unknown
- Lead developer
- Kura Oncology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ziftomenib + olutasidenib is an investigational combination therapy being evaluated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with co-mutations in NPM1 and IDH1. Ziftomenib is an oral small molecule inhibitor of the menin-KMT2A (MLL1) protein-protein interaction, which disrupts leukemogenic gene expression. Olutasidenib is a potent, selective, oral inhibitor of mutated isocitrate dehydrogenase 1 (IDH1). This combination approach, currently being studied in a Phase 1/1b trial led by M.D. Anderson Cancer Center, aims to provide a synergistic therapeutic effect by targeting two distinct oncogenic drivers in this specific AML subpopulation.
- Brand names
- KomziftiRezlidhia
02
Targets
KMT2AIDH1 (Isocitrate dehydrogenase [NADP] cytoplasmic)
Beyond the preview
Go deeper on ziftomenib + olutasidenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ziftomenib + olutasidenib.